HLAVNÍ TÉMA Personalizovaná léčba akromegalie – predikce terapeutické odpovědi 16 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék. 2024;70(1):13-16 / www.casopisvnitrnilekarstvi.cz Závěr V éře precizní medicíny je velmi důležité, aby si endokrinologie stále uvědomovala význam klasifikace nádorů na základě patologického nálezu a hodnoty biomarkerů, které mohou předpovídat dostatečnou terapeutickou odpověď. U mnoha onkologických onemocnění se stalo standardem péče zajistit přesnou subklasifikaci před stanovením terapeutických postupů. V případě hypofýzy se často stále setkáváme s diagnózou „adenom hypofýzy“ nebo třeba „adenom hypofýzy produkující GH“. U pacientů s akromegalií je však nejdůležitější detailní patologické a imunohistochemické vyšetření, které může nasměrovat naše další léčebné kroky. Na to, jaké budou finální algoritmy pro výběr terapie, si však ještě musíme počkat. Tento výstup vznikl v rámci programu Cooperatio, vědní oblasti METD. PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Publikace byla zpracována s využitím uvedené literatury a nebyla publikována ani zaslána k recenznímu řízení do jiného média. Střet zájmů: Žádný. Financování: Ne. Registrace v databázích: N/A. Projednání etickou komisí: N/A. LITERATURA 1. Endocrinology TLD&. Precision medicine: improving accuracy, reducing error. Lancet Diabetes Endocrinol. 1. listopad 2023;11(11):783. 2. Asa SL, Kucharczyk W, Ezzat S. Pituitary acromegaly: not one disease. Endocr Relat Cancer. 2017;24(3):C1-4. 3. Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol. 2022;33(1):6-26. 4. 2021 WHO Classification of Tumors of the Central Nervous System: a summary | Neuro- -Oncology | Oxford Academic [Internet]. [citován 23. leden 2024]. Available from https:// academic.oup.com/neuro-oncology/article/23/8/1231/6311214 5. Starnoni D, Daniel RT, Marino L, et al. Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. Acta Neurochir (Wien). 2016;158(11):2109-21. 6. Abu Dabrh AM, Mohammed K, Asi N, et al. Surgical Interventions and Medical Treatments in Treatment-Naïve Patients With Acromegaly: Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2014;99(11):4003-14. 7. Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–61. 8. Agrawal N, Ioachimescu AG. Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review. Pituitary. 2020;23(5):582-94. 9. Briceno V, Zaidi HA, Doucette JA, Onomichi KB, Alreshidi A, Mekary RA, et al. Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis. Neurol Res. 2017;39(5):387-98. 10. Brue T, Rahabi H, Barry A, et al. Position statement on the diagnosis and management of acromegaly: the French National Diagnosis and Treatment Protocol (NDTP). Ann Endocrinol. 2023;S0003-4266(23)00686-8. 11. Colao A, Auriemma RS, Pivonello R, et al. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. 2016;19:235-47. 12. Gadelha MR, Wildemberg LE, Bronstein MD, et al. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017;20(1):100-8. 13. Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary. 2013;16(4):490-8. 14. Potorac I, Petrossians P, Daly AF, et al. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer. 2016;23(11):871-81. 15. Puig-Domingo M, Resmini E, Gomez-Anson B, et al. Magnetic Resonance Imaging as a Predictor of Response to Somatostatin Analogs in Acromegaly after Surgical Failure. J Clin Endocrinol Metab. 2010;95(11):4973-8. 16. Nista F, Corica G, Castelletti L, et al. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. Front Endocrinol. 2021;12:677919. 17. Fougner SL, Borota OC, Berg JP, et al. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf). 2008;68(3):458–65. 18. Ozkaya HM, Comunoglu N, Sayitoglu M, et al. Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues. Pituitary. 2018;21(4):335-46. 19. Gatto F, Feelders RA, Van Der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, et al. Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly. J Clin Endocrinol Metab. 2013;98(1):E66-71. 20. Wildemberg LEA, Neto LV, Costa DF, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest [Internet]. leden 2013 [cited 10. 12. 2023];36(1). Available from https://doi.org/10.3275/8305 21. Muhammad A, Coopmans EC, Gatto F, et al. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression. J Clin Endocrinol Metab. 2019;104(3):915-24. 22. Iacovazzo D, Carlsen E, Lugli F, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. 2016;174(2):241-50. 23. Soukup J, Hornychova H, Manethova M, et al. Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly. J Cell Mol Med. 2021;25(5):2484-92. 24. Ilie MD, Tabarin A, Vasiljevic A, et al. Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly—A Prospective Study. J Clin Endocrinol Metab. 2022;107(11):2982-91. 25. Puig-Domingo M, Gil J, Sampedro-Nuñez M, et al. Molecular profiling for acromegaly treatment: a validation study. Endocr Relat Cancer. 2020;27(6):375-89. 26. Trouillas J, Sassolas G, Guigard MP, et al. Relationships between pathological diagnosis and clinical parameters in acromegaly. Metab – Clin Exp. 1996;45:53-6. 27. Gil J, Marques-Pamies M, Sampedro M, et al. Data mining analyses for precision medicine in acromegaly: a proof of concept. Sci Rep. 28. květen 2022;12(1):8979. 28. Wildemberg LE, da Silva Camacho AH, Miranda RL, et al. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands. J Clin Endocrinol Metab. 1. červenec 2021;106(7):2047–56. 29. Albano L, Losa M, Barzaghi LR, Niranjan A, Siddiqui Z, Flickinger JC, et al. Gamma Knife Radiosurgery for Pituitary Tumors: A Systematic Review and Meta-Analysis. Cancers. leden 2021;13(19):4998. 30. Pollock BE, Jacob JT, Brown PD, Nippoldt TB. Radiosurgery of growth hormone–producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg. 2007;106(5):833-8. 31. Losa M, Gioia L, Picozzi P, Franzin A, Valle M, Giovanelli M, et al. The Role of Stereotactic Radiotherapy in Patients with Growth Hormone-Secreting Pituitary Adenoma. J Clin Endocrinol Metab. 2008;93(7):2546-52.
RkJQdWJsaXNoZXIy NDA4Mjc=